Voice of the United States report, reports of the American Voice of America, reports of the American Voice of the United States, reports, reports of the United States Voice of America, report, Voice of the United States report, report from the Voice of the United States, report, Voice of the United States report.Over the past year, the antibody drugs of the recycled yuan and Lilly of the American Pharmaceutical Corporation have been the preferred treatment method of early crown disease.However, the laboratory test shows that these two therapies are much lower than the effectiveness of Omikon, because Omikon contains dozens of mutations, making it more difficult for antibodies to attack the virus.

(Washington Comprehensive News) On the occasion of the new wave of epidemics caused by Omikon in the local hospital, American doctors warned another challenge at present: theyTwo standard drugs used to fight coronary infection are unlikely to play a role in this new strain.

The Voice of the United States reported that in the past year, the antibody drugs of the American Pharmaceutical Company Regeneron and Elililly have been the first choice for early crown diseases. This is due to them due to them.Can prevent serious diseases and keep patients away from the hospital.

But the laboratory test shows that these two therapies are much lower than the effectiveness of Omikon, because Omikdon contains dozens of mutations, making it more difficult for antibodies to attack the virus.Although both companies have stated that they can quickly develop new antibodies against Omikon, it is expected to be listed in at least several months.

GlaxoSmithsk drugs are the best choice against Omikon

The third type developed by British pharmaceutical dealer GlaxosmithklineAntibody drugs seem to be the best choice against Omikon, but this drug is not widely used in the United States.

Jonathanli, director of the Laboratory of Harvard/Blagen Virus Professional Laboratory, believes that in view of the current one of the single clone antibody drugs authorized by the US Food and Drug Administration (FDA),The United States will have a shortage of coronary drugs.

According to the US Centers for Disease Control and Prevention (CDC), Delta's strains still account for more than 95%of the cases of crown diseases in the United States.It is expected that it will become the main strain spread across the country within a few weeks.

antibody therapy is to inject human proteins made in the laboratory into the human body to help the immune system fight virus and other infections.Sotrovimab, a monoclonal antibody drug jointly developed by Glasos and VIR Biotechnology, can be combined with less mutation in viruses. This drug has obtained optimistic results in early research against Omikon.

The US Department of Health and Public Service (HHS) said that the current supply of Sotrovimab is extremely limited.The ministry is transporting 55,000 doses of this drug to the states, and it is expected to distribute 300,000 doses in January next year.

U.S. regulatory agencies are expected to quickly approve Pfizer and Merck Crown Diseases.The outside world pays more attention to the antiviral drugs of Pfizer and Merck. It is expected that the US regulators will soon approve these two new drugs.

Paxlovid of Pfizer and Molnupiravir in Merke are oral medicines that can be used at home. Among them, Pfizer's drugs can reduce the hospitalization rate and mortality rate of high -risk patients by nearly 90%.

Andrewpekosz, a virusist of Johns Hopkins, said that such new drugs are expected to make up for the lack of antibody therapy, thereby minimizing the impact brought by Omikon.

However, the initial supply of these two drugs is expected to be limited."We will definitely see the increase in the number of hospitalizations. If we lack antibody drugs, it will definitely cause more patients to be hospitalized if we lack of antibody drugs."